Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 14, Pages -Publisher
MDPI
DOI: 10.3390/ijms21144910
Keywords
DNA damage response; glioblastoma; DDR inhibitors
Funding
- Associazione Italiana per la Ricerca sul Cancro (AIRC)-IG2016 [19069]
- MIUR-JPI-HDHL-NUTRICOG-MiTyrAge [PRIN_2015LZE994_005]
- Italian Ministry of Health [RF-2016-02362022, RF-2016-02363460]
- PhD programme in Molecular and Cellular Biology, University of Rome Tor Vergata
Ask authors/readers for more resources
Glioblastoma multiforme (GBM) is a severe brain tumor whose ability to mutate and adapt to therapies is at the base for the extremely poor survival rate of patients. Despite multiple efforts to develop alternative forms of treatment, advances have been disappointing and GBM remains an arduous tumor to treat. One of the leading causes for its strong resistance is the innate upregulation of DNA repair mechanisms. Since standard therapy consists of a combinatory use of ionizing radiation and alkylating drugs, which both damage DNA, targeting the DNA damage response (DDR) is proving to be a beneficial strategy to sensitize tumor cells to treatment. In this review, we will discuss how recent progress in the availability of the DDR kinase inhibitors will be key for future therapy development. Further, we will examine the principal existing DDR inhibitors, with special focus on those currently in use for GBM clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available